265 related articles for article (PubMed ID: 32297213)
1. Chaperome Networks - Redundancy and Implications for Cancer Treatment.
Yan P; Wang T; Guzman ML; Peter RI; Chiosis G
Adv Exp Med Biol; 2020; 1243():87-99. PubMed ID: 32297213
[TBL] [Abstract][Full Text] [Related]
2. The epichaperome is an integrated chaperome network that facilitates tumour survival.
Rodina A; Wang T; Yan P; Gomes ED; Dunphy MP; Pillarsetty N; Koren J; Gerecitano JF; Taldone T; Zong H; Caldas-Lopes E; Alpaugh M; Corben A; Riolo M; Beattie B; Pressl C; Peter RI; Xu C; Trondl R; Patel HJ; Shimizu F; Bolaender A; Yang C; Panchal P; Farooq MF; Kishinevsky S; Modi S; Lin O; Chu F; Patil S; Erdjument-Bromage H; Zanzonico P; Hudis C; Studer L; Roboz GJ; Cesarman E; Cerchietti L; Levine R; Melnick A; Larson SM; Lewis JS; Guzman ML; Chiosis G
Nature; 2016 Oct; 538(7625):397-401. PubMed ID: 27706135
[TBL] [Abstract][Full Text] [Related]
3. Chaperome heterogeneity and its implications for cancer study and treatment.
Wang T; Rodina A; Dunphy MP; Corben A; Modi S; Guzman ML; Gewirth DT; Chiosis G
J Biol Chem; 2019 Feb; 294(6):2162-2179. PubMed ID: 30409908
[TBL] [Abstract][Full Text] [Related]
4. A Chemical Biology Approach to the Chaperome in Cancer-HSP90 and Beyond.
Taldone T; Wang T; Rodina A; Pillarsetty NVK; Digwal CS; Sharma S; Yan P; Joshi S; Pagare PP; Bolaender A; Roboz GJ; Guzman ML; Chiosis G
Cold Spring Harb Perspect Biol; 2020 Apr; 12(4):. PubMed ID: 30936118
[TBL] [Abstract][Full Text] [Related]
5. Selective targeting of the stress chaperome as a therapeutic strategy.
Taldone T; Ochiana SO; Patel PD; Chiosis G
Trends Pharmacol Sci; 2014 Nov; 35(11):592-603. PubMed ID: 25262919
[TBL] [Abstract][Full Text] [Related]
6. Targeting the Diabetic Chaperome to Improve Peripheral Neuropathy.
Dobrowsky RT
Curr Diab Rep; 2016 Aug; 16(8):71. PubMed ID: 27318486
[TBL] [Abstract][Full Text] [Related]
7. Adapting to stress - chaperome networks in cancer.
Joshi S; Wang T; Araujo TLS; Sharma S; Brodsky JL; Chiosis G
Nat Rev Cancer; 2018 Sep; 18(9):562-575. PubMed ID: 29795326
[TBL] [Abstract][Full Text] [Related]
8. A systematic atlas of chaperome deregulation topologies across the human cancer landscape.
Hadizadeh Esfahani A; Sverchkova A; Saez-Rodriguez J; Schuppert AA; Brehme M
PLoS Comput Biol; 2018 Jan; 14(1):e1005890. PubMed ID: 29293508
[TBL] [Abstract][Full Text] [Related]
9. Combination of Anti-Cancer Drugs with Molecular Chaperone Inhibitors.
Shevtsov M; Multhoff G; Mikhaylova E; Shibata A; Guzhova I; Margulis B
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31652993
[TBL] [Abstract][Full Text] [Related]
10. Inhibiting HSP90 to treat cancer: a strategy in evolution.
Whitesell L; Santagata S; Lin NU
Curr Mol Med; 2012 Nov; 12(9):1108-24. PubMed ID: 22804235
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of HSP90 molecular chaperones: moving into the clinic.
Garcia-Carbonero R; Carnero A; Paz-Ares L
Lancet Oncol; 2013 Aug; 14(9):e358-69. PubMed ID: 23896275
[TBL] [Abstract][Full Text] [Related]
12. Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2.
Gallerne C; Prola A; Lemaire C
Biochim Biophys Acta; 2013 Jun; 1833(6):1356-66. PubMed ID: 23485394
[TBL] [Abstract][Full Text] [Related]
13. Proteomic interrogation of HSP90 and insights for medical research.
Weidenauer L; Wang T; Joshi S; Chiosis G; Quadroni MR
Expert Rev Proteomics; 2017 Dec; 14(12):1105-1117. PubMed ID: 28990809
[TBL] [Abstract][Full Text] [Related]
14. Chaperones as integrators of cellular networks: changes of cellular integrity in stress and diseases.
Palotai R; Szalay MS; Csermely P
IUBMB Life; 2008 Jan; 60(1):10-8. PubMed ID: 18379988
[TBL] [Abstract][Full Text] [Related]
15. [Hsp90--a target for anticancer therapy].
Růcková E; Müller P; Vojtesek B
Klin Onkol; 2011; 24(5):329-37. PubMed ID: 22070013
[TBL] [Abstract][Full Text] [Related]
16. Protein chaperones as anticancer therapy targets.
Sausville E
Clin Adv Hematol Oncol; 2004 Feb; 2(2):92-3. PubMed ID: 16163168
[No Abstract] [Full Text] [Related]
17. The Right Tool for the Job: An Overview of Hsp90 Inhibitors.
Koren J; Blagg BSJ
Adv Exp Med Biol; 2020; 1243():135-146. PubMed ID: 32297216
[TBL] [Abstract][Full Text] [Related]
18. Paradigms for Precision Medicine in Epichaperome Cancer Therapy.
Pillarsetty N; Jhaveri K; Taldone T; Caldas-Lopes E; Punzalan B; Joshi S; Bolaender A; Uddin MM; Rodina A; Yan P; Ku A; Ku T; Shah SK; Lyashchenko S; Burnazi E; Wang T; Lecomte N; Janjigian Y; Younes A; Batlevi CW; Guzman ML; Roboz GJ; Koziorowski J; Zanzonico P; Alpaugh ML; Corben A; Modi S; Norton L; Larson SM; Lewis JS; Chiosis G; Gerecitano JF; Dunphy MPS
Cancer Cell; 2019 Nov; 36(5):559-573.e7. PubMed ID: 31668946
[TBL] [Abstract][Full Text] [Related]
19. Targeting chaperones in transformed systems--a focus on Hsp90 and cancer.
Chiosis G
Expert Opin Ther Targets; 2006 Feb; 10(1):37-50. PubMed ID: 16441227
[TBL] [Abstract][Full Text] [Related]
20. Blocking the chaperone kinome pathway: mechanistic insights into a novel dual inhibition approach for supra-additive suppression of malignant tumors.
Grover A; Shandilya A; Agrawal V; Pratik P; Bhasme D; Bisaria VS; Sundar D
Biochem Biophys Res Commun; 2011 Jan; 404(1):498-503. PubMed ID: 21144839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
